Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.46 |
| ▸ | KDM1B | Q8NB78 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30296659 | 1.00 | KDM1A (0.46) | KDM1AKDM1BKCNH2NPC1RAB9A | |
| SCHEMBL28490129 | 0.91 | KDM1A (0.38) | KDM1AKDM1BNPC1RAB9A | |
| SCHEMBL14774772 | 0.84 | DPP4 (0.33) | KDM1AKDM1B | |
| SCHEMBL30030017 | 0.84 | DPP4 (0.33) | KDM1AKDM1B | |
| SCHEMBL3363763 | 0.83 | KDM1A (0.38) | KDM1AKDM1BKCNH2 | |
| SCHEMBL488821 | 0.82 | GPR84 (0.37) | KDM1AKDM1BKCNH2 | |
| SCHEMBL21521510 | 0.81 | KDM1A (0.38) | KDM1AKDM1BKCNH2 | |
| SCHEMBL16794042 | 0.81 | KDM1A (0.49) | KDM1AKDM1BKCNH2 | |
| SCHEMBL15785464 | 0.81 | KDM1A (0.44) | KDM1AKDM1BKCNH2NPC1RAB9A | |
| SCHEMBL2554312 | 0.81 | KDM1A (0.44) | KDM1AKDM1BKCNH2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4702021-A1 | COMPOUNDS CAPABLE OF MODULATING GPR65 | Pathios Therapeutics Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024224064-A1 | COMPOUNDS CAPABLE OF MODULATING GPR65 | Pathios Therapeutics Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| US-20240239816-A1 | BORONO-PHENYLALANINE DERIVATIVE | STELLA PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| EP-4361159-A1 | BORONO-PHENYLALANINE DERIVATIVE | Stella Pharma Corporation (JP) | 2024-05-01 | — | — | EP | disclosed |
| CN-117545759-A | Derivatives of dihydroxyborylphenylalanine | 斯特拉制药公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-111212830-B | N- (substituted sulfonyl) benzamide derivative and preparation method and medical application thereof | 浙江海正药业股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2694504-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | Afraxis Holdings, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2593428-A2 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109701-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109701-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109701-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2013043232-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2012007868-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007868-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | KDM1A 4193/4885KDM1B 3752/4885KCNH2 878/4885 |
| US-20240239816-A1 | BORONO-PHENYLALANINE DERIVATIVE | SLC7A1, SLC1A5, LATS2 | KDM1A 2483/4885KDM1B 1882/4885KCNH2 4258/4885 |
| US-20130109701-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | KDM1A 1041/4885KDM1B 2065/4885KCNH2 41/4885 |
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | CRBN, GSPT1, GSPT2 | KDM1A 3448/4885KDM1B 3090/4885KCNH2 4880/4885 |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | KDM1A 1033/4885KDM1B 705/4885KCNH2 4836/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | KDM1A 1573/4885KDM1B 1798/4885KCNH2 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.